Farallon Capital Management’s BioAtla BCAB Stock Holding History

Farallon Capital Management’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,600	Closed	-$5.3M	–	304
2021 Q3	$5.3M	Sell	3,600 -14,443	-80%	-$28.1M	0.02%	181
2021 Q2	$38.2M	Sell	18,043 -11,798	-40%	-$26.7M	0.16%	82
2021 Q1	$75.9M	Sell	29,841 -9,500	-24%	-$24.4M	0.38%	56
2020 Q4	$66.9M	Buy	+39,341	New	+$65.8M	0.4%	58

Other funds holding BCAB

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Farallon Capital Management's BCAB Position: Q4 2021 in Review

Farallon Capital Management sold out of BioAtla (BCAB) in Q4 2021, closing a stake of 3,600 shares — an estimated $5.3M sold.

Farallon Capital Management first reported a position in BCAB in Q4 2020 and held it in 4 quarters. The position peaked at $75.9M in Q1 2021. 79 funds tracked by Wall St. Rank hold BCAB as of Q4 2021.

Farallon Capital Management reported no remaining BioAtla position as of Q4 2021 after selling out during the quarter.
Farallon Capital Management sold 3,600 BioAtla shares in Q4 2021, an estimated $5.3M.
Farallon Capital Management first reported a position in BioAtla in Q4 2020 and held it in 4 quarters.
Farallon Capital Management's BioAtla position peaked at $75.9M in Q1 2021.
79 funds tracked by Wall St. Rank held BioAtla as of Q4 2021.

Based on Farallon Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.